Trevi Therapeutics, Inc. (TRVI) Stock Forecast
TRVI analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.82 / 5 from 11 analysts
- Price target
- $28.18 average of analyst targets
- Upside to target
- +137.2% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.13
- 52-week range
- $9.99 – $19.50
TRVI analyst ratings
11 analystsNumber of analysts at each rating.
TRVI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TRVI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.18 | −$0.11 | −$0.08 | −66.2% | 10 |
| Current fiscal year (2026) | −$0.48 | −$0.58 | −$0.34 | −$0.32 | −49.7% | 10 |
| Next fiscal year (2027) | −$0.58 | −$0.76 | −$0.40 | −$0.48 | −20.5% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TRVI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 10 |
TRVI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TRVI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.13 | −$0.13 | −$0.13 | −$0.13 | +3.2% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.47 | −$0.48 | −$0.48 | −$0.48 | −$0.48 | +2.2% | 1 up · 7 down |
| Next fiscal year (2027) | −$0.56 | −$0.57 | −$0.58 | −$0.58 | −$0.58 | +3.4% | 1 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TRVI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TRVI beat in 8 of 12.
What analysts expect from TRVI
11 analysts cover Trevi Therapeutics; their consensus rating is strong buy (4.82 on a 1–5 scale, where 5 is a strong buy). The average price target is $28.18, 137.2% above the latest close of $11.88. Analysts expect earnings of −$0.48 per share for 2026, −49.7% from a year earlier. For 2027 the average estimate is −$0.58 per share. Trevi Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: TRVI income statement, TRVI key metrics, TRVI chart. See the TRVI stock overview for the latest quote and news.
TRVI forecast FAQ
What is Trevi Therapeutics's price target?
The average analyst price target for Trevi Therapeutics is $28.18, 137.2% above the latest close of $11.88.
Is Trevi Therapeutics a buy, hold or sell?
Of 11 analysts covering Trevi Therapeutics, 9 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Trevi Therapeutics's EPS forecast?
Analysts forecast −$0.48 per share for 2026 (range −$0.58 to −$0.34); for 2027 the estimate is −$0.58.
When does Trevi Therapeutics report earnings?
Trevi Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.13.
Does Trevi Therapeutics usually beat earnings estimates?
Trevi Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.